"MIATA"-Minimal Information about T Cell Assays

Sylvia Janetzki, Cedrik M. Britten, Michael Kalos, Hyam I. Levitsky, Holden T. Maecker, Cornelius J M Melief, Lloyd J. Old, Pedro Romero, Axel Hoos, Mark M. Davis

Research output: Contribution to journalArticle

Abstract

Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.

Original languageEnglish (US)
Pages (from-to)527-528
Number of pages2
JournalImmunity
Volume31
Issue number4
DOIs
StatePublished - Oct 16 2009

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases
  • Immunology

Fingerprint Dive into the research topics of '"MIATA"-Minimal Information about T Cell Assays'. Together they form a unique fingerprint.

  • Cite this

    Janetzki, S., Britten, C. M., Kalos, M., Levitsky, H. I., Maecker, H. T., Melief, C. J. M., Old, L. J., Romero, P., Hoos, A., & Davis, M. M. (2009). "MIATA"-Minimal Information about T Cell Assays. Immunity, 31(4), 527-528. https://doi.org/10.1016/j.immuni.2009.09.007